A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease

scientific article published on 06 April 2019

A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.OPHTHA.2019.03.050
P698PubMed publication ID30965064

P50authorSidney WeissQ57095093
P2093author name stringRanjan P Malhotra
Barry A Schechter
John D Sheppard
Angela Justice
Damien F Goldberg
P433issue9
P921main subjecteye diseaseQ3041498
P304page(s)1230-1237
P577publication date2019-04-06
P1433published inOphthalmologyQ7098109
P1476titleA Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease
P478volume126

Reverse relations

cites work (P2860)
Q89939043A Review of Topical Cyclosporine A Formulations-A Disease-Modifying Agent for Keratoconjunctivitis Sicca
Q89536542Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
Q91632324Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease

Search more.